SciBase: Interim report

The second quarter in figures

· Total net sales amounted to TSEK 918 (258).

· The loss after tax amounted to TSEK 10,939 (11,552).

· The loss per share amounted to SEK 1.80 (2.32).

· The cash flow from current operations was negative in the amount of TSEK 13,858 (7,959).

The half-year in figures

· Total net sales amounted to TSEK 1,975 (322).

· The loss after tax amounted to TSEK 20,118 (20,564).

· The loss per share amounted to SEK 3.63 (4.13).

· The cash flow from current operations was negative in the amount of TSEK 23,055(18,209).

Important events during the quarter

· In April, SciBase announced its intention to launch an Initial Public Offering and listing on Nasdaq First North.

· At an Extraordinary General Meeting on April 28, resolutions were taken to:

- introduce a share-based incentive program,

- consolidate shares and reduce the share capital,

- authorize the Board to make decisions regarding new share issues

· The Company completed a rights issue that raised MSEK 165 before issue costs. The Offering was significantly oversubscribed, resulting in a substantially broadened shareholder base consisting of both institutions and private shareholders. .

· The Company’s shares were listed on Nasdaq First North on June 2nd.

· Vinnova granted MSEK 3.9 for the development of the next generation device to SciBase and KTH.

· In April, an exclusive distributor agreement for the Austrian market was signed with Intramed Handels GesmbH.

· The Company expanded its sales resources in Germany.

· In April, SciBase established a Scientific Advisory Board consisting of international experts in the field of skin cancer

· The Company received an additional US patent approval.

Important events after the end of the period

· The Company announced that Pareto Securities has exercised the possibility to, in connection with the initial public offering of SciBase Holding AB (publ) ("SciBase”), carry out stabilization-like transactions.

Financial overview

*Adjusted for in May 2015 performed reversed split, 40:1

About SciBase and Nevisense

SciBase AB is a Swedish medical technology company, headquartered in Stockholm that has developed a unique point-of-care device for the accurate detection of malignant melanoma. Its product, Nevisense, helps doctors to detect malignant melanoma, the most dangerous type of skin cancer. SciBase was founded by Stig Ollmar, Associate Professor at The Karolinska Institute in Stockholm, Sweden. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia, and is awaiting FDA clearance in the United States. Nevisense is based on a method called Electrical Impedance Spectroscopy (EIS), which uses the varying electrical properties of human tissue to categorize cellular structures and thereby detect malignancies. SciBase is listed on Nasdaq First North ("SCIB"). Avanza is Certified Adviser. Further information is available on www.scibase.com.

This information was brought to you by Cision http://news.cision.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20150819006338/en/